Wave Life Sciences regains full rights to WVE-006

Wave Life Sciences (WVE) announced it has regained full rights to WVE-006, an investigational GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency, AATD, from GSK (GSK). This follows agreement with GSK, whose respiratory portfolio is focused on large-scale diseases, that Wave is well placed to efficiently advance the WVE-006 program in AATD. This agreement was made prior to data becoming available from the next cohort of the RestorAATion-2 clinical trial, which remains on track for the first quarter of 2026. Wave is now accelerating its registrational strategy for WVE-006 and plans to engage with the U.S. Food and Drug Administration on a potential accelerated approval pathway, with regulatory feedback expected mid-2026.